MedStar Union Memorial Hospital, Baltimore, USA
Case Report
Pembrolizumab induced Bell?s Palsy in Triple Negative Breast Cancer: A case report
Author(s): Greeshma N Gaddipati
Pembrolizumab has been approved by the Food and Drug Administration (FDA) to treat multiple cancers one of which is triple-negative breast cancer positive for Programmed Cell Death Ligand 1 (PD-L1) protein. Multiple immune-related Adverse Drug Reactions (irADRs) have been reported with pembrolizumab affecting various organ systems. Bell's palsy is one such irADR that has been previously reported with Immune Checkpoint Inhibitors (ICI) use in other cancers, but it has not been reported in triple-negative breast cancer. We present a case of a 35-year-old woman with Bell's Palsy (lower motor neuron type), with a history of triple negative stage 2 invasive ductal carcinoma receiving neoadjuvant chemoimmunotherapy with pembrolizumab. She presented with right-sided facial drooping affecting the upper and lower part with impaired sensation on the left side of the face. After an exten.. View More»
DOI:
10.35248/2332-2594.22.10(4).001-003